FDA Provides Facts About Zohydro

<!– –> <!– Page Last Updated: 04/30/2014 –> Page Last Updated: 04/30/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

September 20, 2010: Cardiovascular and Renal Drugs Advisory Committee Meeting Announcement

Agenda The committee will discuss new drug application (NDA) 22–512, dabigatran etexilate mesylate capsules, sponsored by Boehringer Ingelheim Pharmaceuticals, Inc., for the proposed indication of prevention of stroke in patients with atrial fibrillation (abnormally rapid contractions of the atria, the upper chambers of the heart). Meeting Materials FDA intends to make background material available to…

Opioid Patient-Prescriber Agreement

A Tool for Shared Decision-Making in the Treatment of Pain As part of a pain treatment regimen, patients may be prescribed opioid analgesics. Opioids, like all drugs, have risks. Prescribing errors and inappropriate use of opioid analgesics increase risk and can lead to serious harm, including death. This harm is preventable. In April 2011, FDA Safe…

How to Report a Shortage or Supply Issue

<!– –> <!– Page Last Updated: 02/14/2014 –> Page Last Updated: 02/14/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

Small Business and Industry Education Series

<!– –> <!– Page Last Updated: 02/13/2014 –> Page Last Updated: 02/13/2014 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.